Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia

Thrombosis Research

Volumn 126, Issue 3, 2010, Pages

  Tehrani, Sara ^a   Mobarrez, Fariborz ^a   Antovic, Aleksandra ^a   Santesson, Pia ^a   Lins, Per Eric ^a   Adamson, Ulf ^a   Henriksson, Peter ^a   Wallén, N Håkan ^a   Jörneskog, Gun ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

Atorvastatin; Diabetes; Fibrin network; Microparticles

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FIBRIN; GLYCOPROTEIN IIIA; GLYCOSYLATED HEMOGLOBIN; PADGEM PROTEIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FIBRINOGEN BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PERMEABILITY; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PLATELETS; C-REACTIVE PROTEIN; CELL-DERIVED MICROPARTICLES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FIBRIN; FIBRINOLYTIC AGENTS; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTEGRIN BETA3; MIDDLE AGED; P-SELECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRROLES; SWEDEN; THROMBIN; THROMBOPLASTIN; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956267128     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.05.023     Document Type: Article

References (41)

1. C. Watala, M. Boncler, and P. Gresner Blood platelet abnormalities and pharmacological modulation of platelet activity in patients with diabetes mellitus Pharmacol Rep 57 2005 42 58
2. O.P. Ganda, and C.F. Arkin Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes Diabetes Care 15 1992 1245 1250
3. A. Ceriello, C. Taboga, R. Giacomello, E. Falleti, G. De Stasio, and E. Motz Fibrinogen plasma levels as a marker of thrombin activation in diabetes Diabetes 43 1994 430 432
4. B. Blombäck, K. Carlsson, K. Fatah, B. Hessel, and R. Procyck Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation Thromb Res 5 1994 521 538
5. J.W. Weisel Structure of fibrin: impact on clot stability J Thromb Haemost 5 2007 116 124
6. B. Blombäck, K. Carlsson, B. Hessel, A. Liljeborg, R. Procyk, and N. Åslund Native fibrin gel networks observed by 3D microscopy, permeation and turbidity Biochim Biophys Acta 997 1989 96 110
7. J.P. Collet, D. Park, C. Lesty, J. Soria, C. Soria, and G. Montalescot Influence on fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy Arterioscler Thromb Vasc Biol 20 2000 1354 1361
8. G. Jörneskog, N. Egberg, B. Fagrell, K. Fatah, B. Hessel, and H. Johnsson Altered properties of the fibrin gel structure in patients with IDDM Diabetologia 39 1996 1519 1523
9. G. Jörneskog, L. Hansson, N.H. Wallen, M. Yngen, and M. Blombäck Increased plasma fibrin gel porosity in patients with type 1 diabetes during continuous subcutaneous insulin infusion J Thromb Haemost 1 2003 1195 1201
10. R.J. Glynn, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med 360 2009 1851 1861
11. H. Colhoun, J.D. Betteridge, P.N. Durington, G.A. Hitman, A.W. Neil, and S.J. Livingstone Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
12. R. Collins, J. Armitage, S. Parish, P. Sleight, R. Peto Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with Simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 9374 2003 2005 2016
13. A. Undas, K. Brummel-Ziedins, and K.G. Mann Statins and blood coagulation Arterioscler Thromb Vasc Biol 2 2005 287 294
14. A. Notarbartolo, G. Davì, M. Averna, C.M. Barbagallo, A. Ganci, and C. Giammarresi Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia Arterioscler Thromb Vasc Biol 15 1995 247 251
15. M. Yngen, C.G. Östenson, H. Hu, N. Li, P. Hjemdahl, and N.H. Wallén Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation Diabetologia 47 2004 537 540
16. P. Siljander, O. Carpen, and R. Lassila Platelet-derived microparticles associate with fibrin during thrombosis Blood 87 1996 4651 4663
17. D.W. Sommeijer, K. Joop, A. Leyte, P.H. Reitsma, and H. ten Cate Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes J Thromb Haemost 3 2005 1168 1171
18. F. Mobarrez, J. Antovic, N. Egberg, M. Hansson, G. Jörneskog, and K. Hultenby A multicolor flow cytometric assay for measurement of platelet-derived microparticles Thromb Res 125 2010 Mar e110 e116
19. S. He, H. Cao, A. Antovic, and M. Blombäck Modifications in flow measurement of fibrin gel permeability: a possible tool for determining the fibrinolytic potential in clinical materials Blood Coagul Fibrinolys 16 2005 61 67
20. B. Blombäck, and M. Okada Fibrin gel structure and clotting time Thromb Res 25 1982 51 70
21. H.C. Hemker Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system J Thromb Haemost 5 2006 553 561
22. A. Undas, M. Celinska-Löwenhoff, T. Löwenhoff, and A. Szczeklik Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary heart disease J Thromb Haemost 4 2005 1029 1036
23. A. Bröijersén, A. Hamsten, A. Silveira, K. Fatah, A.H. Goodall, and M. Eriksson Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII J Thromb Haemost 76 1996 171 176
24. P.H. Wirtz, U. Ehlert, L. Emini, K. Rüdisüli, S. Groessbauer, and J. Gaab Anticipatory cognitive stress appraisal and the acute procoagulant stress response in men Psychosom Med 6 2006 851 858
25. S. Nomura, M. Suzuki, K. Katsura, G.L. Xie, Y. Miyazaki, and T. Miyake Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus Atherosclerosis 116 1995 235 240
26. K. Jurk, and B.E. Kehrel Platelets: physiology and biochemistry Semin Thromb Hemost 31 2005 381 392
27. O. Panes, V. Matus, C.G. Sáez, T. Quiroga, J. Pereira, and D. Mezzano Human platelets synthesize and express functional tissue factor Blood 109 2007 5242 5250
28. H. Schwertz, N.D. Tolley, J.M. Foulks, M.M. Denis, B.W. Risenmay, and M. Buerke Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets J Exp Med 11 2006 2433 2440
29. S. Butenas, B.A. Bouchard, K.E. Brummel-Ziedins, B. Seren-Parhami, and K.G. Mann Tissue factor activity in whole blood Blood 105 2005 2764 2770
30. B. Osterud, and E. Bjorklid Sources of tissue factor Semin Thromb Hemost 1 2006 11 23
31. U. Rauch, D. Bonderman, B. Bohrmann, J.J. Badimon, J. Himber, and M.A. Riederer Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor Blood 96 2000 170 175
32. M.T. Santos, M.P. Fuset, M. Ruano, A. Moscardó, and J. Valles Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction Am J Cardiol 104 2009 1618 1623
33. P. Lijnen, D. Echevaría-Vázquez, and V. Petrov Influence of cholesterol-lowering on plasma membrane lipids and function Methods Find Exp Clin Pharmacol 18 1996 123 136
34. 2+ and membrane dynamics in patients with primary hypercholesterolemia; effects of pravastatin Arterioscler Thromb Vasc Biol 15 1995 759 764
35. S. Falati, Q. Liu, P. Gross, G. Merrill-Skoloff, J. Chou, and E. Vandendries Accumulation of Tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin Glycoprotein Ligand 1 and platelet P-selectin J Exp Med 197 2003 1585 1598
36. J. Chou, N. Mackman, G. Merrill-Skolff, B. Pedersen, B.C. Furie, and B. Furie Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation Blood 104 2004 3190 3197
37. I. Seljeflot, S. Tonstad, I. Hjermann, and H. Arnesen Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease Thromb Res 105 2002 285 290
38. A. Undas, M. Celinska-Löwenhoff, M. Kaczor, and J. Musial New nonlipid effects of statins and their clinical relevance in cardiovascular disease Thromb Haemost 91 2004 1065 1077
39. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
40. I. Jialal, E. Miguelino, S.C. Griffen, and S. Devaraj Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes J Clin Endocrinol Metab 92 2007 3136 3140
41. G.K. Dogra, G.F. Watts, D.C. Chan, and K. Stanton Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria Diabet Med 22 2005 239 242